Aim: We report the characteristics of intermittent cancer pain. In addition, we propose a new clinically based classification. Methods: Consecutive patients with cancer referred to our palliative medicine service were consented and underwent a comprehensive pain evaluation including available laboratory and radiological studies, at the time of initial contact. Results and discussion: In total, 100 consecutive patients reported 158 different pain sites. Pain temporal pattern observed was 60% of patients had continuous (CP) plus intermittent pain (IP); 29% IP alone; and 11% CP alone. The etiology of IP was somatic (58%), visceral (24%), neuropathic (7%), and mixed (11%). Median duration of IP was 4 months with a median daily frequency of 4 episodes. Consequently, we propose that IP be classified into IP alone or nonbreakthrough pain (NBP; because there is no underlying CP or around-the-clock [ATC] opioids used) and breakthrough pain (BP; because there is underlying CP or/and ATC opioids used). We propose that both BP and NBP be each subclassified into 3 categories: (1) incident, (2) nonincident, and (3) mixed. In addition, a 4th category exclusive to BP: end-of-dose failure. Incident pains made up (N ¼ 42, 47%) nearly half of all IP. According to our classification, incident pain was part of BP in 41% (N ¼ 25) or NBP in 58% (N ¼ 17). Incident NBP received less treatment than incident BP, and it was less controlled. Conclusion: (1) Intermittent pain is a major problem in patients with cancer, (2) NBP is a common but under-recognized form of cancer pain, (3) NBP is less defined and controlled than BP, (4) incident NBP accounts for 40% of all incident cancer pain, and (5) variable IP definitions and classifications make comparisons between studies difficult.
Introduction
Pain occurs in 60% to 80% of those with advanced cancer. 1 Painstaking efforts have been invested with success to better understand and develop treatment guidelines; however, gaps remain. ''Transient pain'' remains a frequent and troublesome problem. 2 Breakthrough pain (BP), incident pain, intermittent pain (IP), transient pain, and episodic pain are widely but variably used terms for these events. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Although multiple terminologies are not an uncommon occurrence in medicine, for BP there seems to be confusion as to the term's connotation. In an international survey of BP characteristics, the prevalence significantly changed when reported by physicians of different countries. 16 ''Breakthrough pain'' has been defined differently by different authors (Table 1) . [7] [8] [9] [10] [11] [12] Furthermore, incident pain has been defined as involuntary and/or voluntary pain brought about by movement, standing, coughing, bowel movement, or other precipitating factors. 7, 17 No consensuses on definitions exist, so planning the most appropriate treatment using specific assessments for precise pain characterization is not possible. ''Transient pain'' is often a poorly managed temporal pain pattern, which adversely influences both prognosis and quality of life. 17 In our experience, the opioid dose necessary for analgesia at rest may be insufficient for IP. A significant increase in the around-the-clock (ATC) dose may cause unacceptable toxicity without preventing IP. 4, 18, 19 Physicians should use 2 major pain treatment strategies: a continuous pain strategy (ATC dosing) and an IP strategy (rescue dosing). If continuous pain is then controlled but not the intermittent BP, the frequency or doses of the rescue medication should be altered independent of the ATC dose even if BP is mild but bothersome to the patient.
In this study, we report the characteristics of IP in patients with cancer at initial presentation to a palliative medicine program and also propose a new clinically based classification for intermittent cancer pain.
Patients and Methods
During a period of about 3 months, consecutive patients referred to the Palliative Medicine Program of the Cleveland Clinic Foundation were screened for inclusion in this study. Patients were eligible if they were diagnosed with cancer and had pain within the past month. They were ineligible if they were pain free, unable to provide a reliable history, having language barrier, or if they declined verbal consent. At the time of consultation, a comprehensive pain evaluation was recorded including available laboratory and radiological studies. As part of the pain history, the attending physician completed a standard pain assessment form designed for routine clinical use. 20 Any pain was recorded irrespective of intensity. Medications, dosages, and response to pain medications were determined by patient history. The evaluating physicians determined anatomical location and pathophysiological mechanisms for the pains after review of clinical and radiological data. Details of the methodology are available elsewhere. 20 The relation between the rescue morphine dose and the duration and percentage of IP relief was analyzed. All percentages were rounded off to the nearest whole number. Results are reported as numbers of patients. The w 2 goodness-of-fit test was used to test for differences between pain patterns.
Results

Demographics
Of the 156 consecutive referrals, 100 were eligible. Patients reported 158 separate pain sites. In total, 84 had IP. On examining the temporal characteristic of IP, 70% had IP plus continuous pain and 30% IP alone ( Figure 1 ). In those with IP plus continuous pain, IP etiology resembled the accompanying continuous pain in most. All patients, with a median age of 62 years (range 20-90), were diagnosed with cancer. Most were Caucasian (81%) and had a median Eastern Cooperative Oncology Group (ECOG) performance score of 3 (range 1-4). In total, 60% were men. The most common diagnosis was lung cancer (11%), then cancers of unknown primary (8%), breast (8%), and bladder (5%). Intermittent pain, in general, was more common in men (P ¼ .02), but pain severity did not correlate with gender.
Intermittent Pain
The etiologies of the IP were somatic (58%), visceral (24%), neuropathic (7%), and mixed (11%). Overall, the intensity of the IP was severe in 16%, moderate in 44%, and mild in 40%. The median duration of IP was 4 months with a median daily frequency of 4 episodes.
Analgesic Prescribing
In total, 50% of those with IP plus continuous pain were receiving either as-needed analgesics or regularly scheduled opioids without any scheduled (ATC) or rescue dose (pro re nata [PRN]) analgesics, respectively. The rest were prescribed either ATC and PRN medication (45%) or no analgesics at all (5%). Twenty-five percent of those with IP alone had not been prescribed any opioid. The most common PRN medications were oral oxycodone/acetaminophen, followed by parenteral morphine and immediate-release oral morphine. Intermittent pain frequency, duration, and response to rescue medication are given in Table 2 . Intermittent pain responded to rescue medications for 3 hours or more in only 30% of the patients. The opioid responsiveness of IP was similar, regardless of etiology or character; there was no relationship between morphine rescue dose and either duration or percentage of IP relief. Incident pain made up 40% of all IP. Incident pain was present in conjunction with continuous pain or alone (Figure 1 ); the identified etiology was similar in either case. Incident pain with continuous pain was more likely to be treated than incident pain without continuous pain.
Discussion
This is the first report to specifically describe the temporal types of intermittent cancer pain without preconceived definitions. This allowed us to detect all pains present (regardless of severity) and consequently propose an unbiased IP classification.
We propose a new IP classification ( Figure 2 ):
Intermittent pain only (nonbreakthrough pain [NBP]):
Episodic pain of any intensity without any continuous pain and in the absence of prescribed ATC analgesics. Nonbreakthrough pain would be subclassified into incident, nonincident, and mixed pains.
Continuous plus IP (BP):
Episodic worsening of pain of any intensity on a background of continuous pain of any intensity or prescribed ATC analgesic. It would be subclassified similar to NBP (incident, nonincident, mixed), in addition to end-of-dose failure.
Other useful definitions are as follows:
Incident pain is intermittent but predictable pain related to a specific precipitant, which may be voluntary (eg, after eating) or involuntary (eg, with cough or sneeze). Incident pain may, therefore, be either BP or NBP in character as it may occur with or without a background of continuous pain or prescribed ATC analgesics. Nonincident pain is IP with no apparent precipitating factor. End-of-dose failure is IP, which consistently occurs before the scheduled ATC dose. It usually indicates an inadequate ATC analgesic dose.
Previous reports have reported breakthrough and incident pain as one and the same experience; our data suggest otherwise. 13 Nonbreakthrough pain as a category has not been reported before, even though we found it to be common, accounting for nearly a third of all IP reported. Breakthrough pain in our study was common. Prevalence studies suggest that BP is common but reports vary 16 based on the definitions used. A survey of 245 hospice patients revealed that 218 (89%) had BP. 21, 22 A survey of 164 patients with cancer noted that 51% had BP. 2 It is noteworthy that the identified etiologies in our study resembled those of patients admitted to a hospice.
Definitions
Prior definitions of cancer pain, especially, IP are an inadequate guide to patient management because all pain intensities were not included ( Table 1 ). In addition, some definitions are confusing and hard to understand (International Association for the Study of Pain [IASP] classification of chronic pain; 1986). We believe it is the temporal pattern of pain, which is of primary importance in determining analgesic scheduling. Failure to identify these temporal pain patterns may result in inadequate analgesic prescribing. Our population was seen as palliative medicine consultations, while other studies involved persons referred to a pain service. 2, 8 We would have anticipated more BP (not less) in those studies. Nonbreakthrough pain, which has not been reported before, is common and accounted for just under a third of all cancer pains. Incident pain (whether BP or NBP) seems under-reported in the literature, as in our population it made up almost half of all IPs. The proportions of men and women with bone metastases were the same and do not explain the greater prevalence of IP in men. This may be due to gender differences in pain thresholds or primary site of cancer.
Inadequate Treatment
Intermittent pain, in general (and incident pain in particular), may be more difficult to treat than continuous pain. [23] [24] [25] In our study, among the IPs, a significant minority were untreated before assessment. Incident NBP received less treatment than incident BP. This may be due to (1) the unpredictable nature of NBP and the better defined nature of BP, (2) poor assessment due to inadequate knowledge of NBP and its treatment, 
Pain Classification
Based on these observations, we recommend that (1) 
Conclusions
We conclude that (1) IP is a major problem in patients with cancer, (2) intermittent NBP is common in cancer, (3) intermittent incident NBP is common and accounts for 40% of the incident cancer pain, (4) variable definitions and classifications of IP make comparisons between studies difficult, (5) there was no relation between rescue analgesic doses and degree or duration of IP relief, (6) the etiology of IP was somatic (58%), visceral (24%), neuropathic (7%), or mixed 16% whether BP or NBP in nature, and (7) incident pain is the most common single cause of intermittent cancer pain whether BP or NBP in nature.
